Methyl 5-(3-cyanophenyl)isoxazole-3-carboxylate, 95.0%, 250mg

(1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylsulfonyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol, 98%, 100mg

4-METHYL-4,5,6,7-TETRAHYDROTHIENO[3,2-C]PYRIDINE, 97.0%, 250mg

3-Fluoro-4-methoxybenzimidamide, 98%, 1g

4-[2-(4-Bromo-2-fluorophenoxy)phenyl]-3-buten-2-one, 1g

trans-Cinnamic Acid [Matrix for MALDI-TOF/MS]>99.5%(GC)(T)1g

(S)-2-(((2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)carbamoyl)benzoic acid, 97%, 10mg

Methyl 1-(4-chlorophenyl)cyclopropanecarboxylate, 95.0%, 5g

1,3-Dimethylpyrazole, 98.0%, 100g

N-(Cyclopropylmethyl)-N-propylamine, 97.0%, 1g

Bis(2-chloroethyl) carbonate, 98%, 10g

(1S,2S)-N,N'-Dimethyl-N,N'-bis(3,3-dimethylbutyl)cyclohexane-1,2-diamine>94.0%(GC)1g

1-BOC-3-(AMINOMETHYL)AZETIDINE-3-CARBOXYLIC ACID, 95.0%, 250mg